Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough.
Service de pneumologie B et transplantation pulmonaire, Hôpital Bichat, APHP, Paris, France INSERM U1152, Université Paris Diderot-Paris 7, France gthabut@gmail.com.
Gabriel
G
Thabut
INSERM U1152, Université Paris Diderot-Paris 7, France Service de pneumologie A, Hôpital Bichat, APHP, Paris, France.
Bruno
B
Crestani
Centre d'épidémiologie Clinique, Groupe Hospitalier Cochin - Hôtel Dieu, Paris, France INSERM U1153, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Raphaël
R
Porcher
National Institute for Health Research Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
Luca
L
Richeldi
D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data*; D003625:Data Collection; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D014797:Vital Capacity / Q000187:drug effects
D007211:Indoles; D011728:Pyridones; C093844:pirfenidone; C530716:nintedanib